MSOS: The Question Is Not If, But 'When' The Rescheduling Will Occur

I reiterate a Buy rating on AdvisorShares Pure US Cannabis ETF, emphasizing its compelling risk-return profile despite recent volatility. MSOS trades at 1.7x sales, below its historical average of 2x, offering a 17.6% upside to a $4.45 target if multiples revert. Regulatory progress is slow but ongoing; reclassification appears a matter of 'when,' not 'if,' with catalysts tied to legislative and credit access developments.